character
genet
variat
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
transmit
beij
area
epidem
outbreak
sequenc
fulllength
gene
sarscov
hospit
sar
patient
unit
beij
hospit
viral
rna
templat
sgene
amplif
directli
extract
raw
clinic
sampl
includ
plasma
throat
swab
sputum
stool
cours
epidem
beij
area
use
taclon
assay
direct
analysi
nest
revers
transcriptionpolymeras
chain
reaction
product
sequenc
one
hundr
thirteen
sequenc
variat
nine
recurr
variant
site
identifi
analyz
sgene
sequenc
compar
strain
sarscov
among
eight
variant
site
think
first
document
find
demonstr
coexist
sgene
sequenc
without
substitut
compar
sampl
analyz
patient
result
determin
analysi
clone
sequenc
repres
nucleotid
substitut
variant
site
detect
repres
nucleotid
site
ident
one
refer
sequenc
analyz
sequenc
b
sar
sever
acut
respiratori
syndrom
sw
throat
swab
pl
plasma
sp
sputum
st
stool
c
number
repres
ratio
refer
variant
nucleotid
detect
site
analyz
clone
sequenc
novel
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
implic
caus
agent
worldwid
outbreak
sar
first
month
march
june
beij
case
death
sar
poor
fidel
rnadepend
rna
polymeras
genet
variat
typic
form
heterogen
viru
pool
rna
viru
popul
includ
coronavirus
mous
hepat
viru
mhv
featur
make
virus
highli
adapt
contribut
difficulti
prevent
control
viral
diseas
sarscov
singlestrand
rna
viru
report
rel
less
variabl
analys
limit
number
viral
isol
collect
furthermor
sarscov
quasispeci
document
mani
rna
virus
includ
hepat
c
viru
hcv
hiv
mhv
sar
outbreak
beij
sar
patient
hospit
treat
unit
beij
hospit
includ
first
cluster
casepati
area
character
genet
variat
among
sarscov
transmit
beij
area
sequenc
fulllength
gene
sarscov
hospit
sar
patient
sinc
glycoprotein
play
key
role
virushost
interact
predict
main
target
immun
respons
sampl
analyz
repres
timespan
epidem
exclud
culturederiv
artifact
estim
mutat
heterogen
viral
rna
directli
extract
raw
clinic
sampl
taclon
assay
use
direct
analysi
revers
transcriptasepolymeras
chain
reaction
rtpcr
product
compar
sequenc
previous
document
sgene
sequenc
sarscov
patient
studi
hospit
unit
confirm
diagnosi
sar
sampl
patient
includ
plasma
throat
swab
sputum
stool
store
extract
viral
rna
total
rna
sampl
sarscovposit
patient
detect
use
bni
primer
recommend
world
health
organ
initi
use
sgene
amplif
gener
six
overlap
fragment
cover
fulllength
sgene
sequenc
see
nest
rtpcr
figur
includ
sequenc
analysi
result
rna
sampl
patient
includ
studi
tabl
patient
receiv
ribavirin
steroid
combin
therapi
rna
extract
perform
biosafeti
level
laboratori
rna
extract
directli
plasma
sampl
sputum
sampl
shaken
min
equal
volum
acetylcystein
sodium
chlorid
follow
isol
supernat
centrifug
g
x
min
throat
swab
stool
sampl
suspend
phosphatebuff
salin
pb
contain
uml
rnasin
promega
madison
wi
shaken
min
follow
isol
supernat
centrifug
mention
rna
extract
accord
manufactur
instruct
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
screen
rna
sarscov
base
method
drosten
et
al
sgene
amplif
pair
primer
design
use
macvactor
comput
softwar
accelri
inc
san
diego
ca
base
strain
sarscov
genbank
access
among
six
pair
senseantisens
use
outer
primer
six
pair
senseantisens
use
inner
primer
six
pair
senseantisens
design
direct
rtpcr
product
sequenc
sequenc
cover
fulllength
gene
amplifi
separ
six
overlap
fragment
figur
onestep
rtpcr
kit
qiagen
use
revers
transcript
first
round
pcr
amplif
outer
primer
thermal
cycl
consist
min
min
cycl
decreas
everi
cycl
min
cycl
min
afterward
product
use
templat
second
round
pcr
amplif
rtpcr
product
purifi
qiaquick
pcr
purif
kit
qiagen
qiaquick
gel
extract
kit
qiagen
final
volum
elut
ligat
transform
perform
accord
manufactur
instruct
use
pgemt
vector
system
ii
promega
transform
select
lbagar
plate
contain
ampicillin
xgal
isopropylthiogalactosid
escherichia
coli
white
clone
ad
ml
lb
cultur
overnight
grow
vigor
shake
plasmid
purifi
qiaprep
spin
miniprep
kit
qiagen
recombin
plasmid
sampl
sequenc
analysi
screen
electrophoresi
agaros
contain
ethidium
bromid
sgene
fragment
four
six
clone
screen
verifi
variat
addit
clone
gener
independ
prepar
rnaderiv
rtpcr
product
sequenc
two
four
independ
experi
clone
plasmid
prepar
differ
rtpcr
product
directli
sequenc
confirm
dna
sequenc
obtain
use
autom
abi
sequenc
appli
biosystem
inc
foster
citi
ca
clone
plasmid
primer
use
twodirect
sequenc
reaction
pcr
product
specif
primer
sens
antisens
use
twodirect
sequenc
reaction
analysi
comparison
nucleotid
amino
acid
sequenc
carri
dnastar
comput
softwar
dnastar
inc
madison
wi
gene
sequenc
strain
taken
refer
variat
analysi
design
six
pair
primer
six
overlap
sgene
fragment
amplifi
nest
rtpcr
rna
sampl
howev
rna
sampl
initi
includ
studi
though
posit
sarscov
bni
primer
fail
simultan
gener
six
overlap
sgene
fragment
exclud
sequenc
analysi
disintegr
viru
low
viral
load
raw
sampl
like
account
failur
one
hundr
thirteen
sequenc
variat
distribut
nine
variant
site
identifi
analyz
sequenc
compar
refer
strain
sarscov
isol
tissuecultur
propag
sampl
use
refer
strain
studi
except
one
site
posit
variant
site
knowledg
document
human
seven
nine
variant
site
nonsynonym
figur
show
identifi
variant
site
compar
refer
sequenc
identifi
novel
variant
site
coexist
sequenc
without
sgene
substitut
sarscov
theoret
replic
rna
viru
express
rang
genet
phenotyp
variant
potenti
gener
novel
virion
may
select
respons
environment
pressur
rna
virus
gener
toler
high
level
mutagenesi
limit
genet
complex
mutat
potenti
pathogen
eg
give
viru
immun
neutral
antibodi
cytotox
cell
antivir
drug
dynam
error
copi
sequenc
decomposit
timedepend
hiv
infect
exampl
one
adapt
substitut
env
gene
occur
everi
month
viral
gener
averag
across
patient
studi
higher
variat
frequenc
gene
identifi
sarscov
compar
previou
report
differ
may
due
broader
sampl
collect
cover
longer
timespan
infect
addit
sinc
viru
isol
passag
cultur
whole
mutant
repertoir
like
detect
sinc
revers
mutat
occur
cell
cultur
observ
like
reflect
real
situat
vivo
variat
unlik
result
taq
polymeras
error
sinc
repeat
experi
variat
prepar
independ
rna
rtpcr
product
use
platinum
pfx
dna
polymeras
high
fidel
confirm
result
case
could
exclud
possibl
variat
defect
genom
howev
fact
variat
remain
detect
sequenc
two
three
specimen
patient
obtain
differ
time
suggest
variat
might
activ
extens
vivo
sequenc
without
substitut
compar
simultan
detect
sequenc
seven
sampl
suggest
exist
sarscov
quasispeci
furthermor
sgene
sequenc
differ
sampl
collect
differ
time
patient
show
similar
exactli
ident
variat
profil
four
particip
patient
tabl
impli
dynam
mutat
process
may
exist
vivo
tabl
summar
variat
occur
analyz
sgene
sequenc
individu
sar
patient
one
nonsynonym
chang
observ
posit
within
heptad
repeat
hr
domain
thought
import
viru
entri
previou
studi
mhv
show
would
effect
viru
infect
stage
rule
possibl
chang
affect
biolog
outcom
observ
coexist
sgene
sequenc
without
substitut
timedepend
variat
profil
patient
observ
suggest
possibl
exist
sarscov
quasispeci
acut
infect
studi
howev
limit
clinic
sampl
collect
difficulti
directli
amplifi
fulllength
gene
raw
clinic
sampl
restrict
extens
studi
dynam
mutant
distribut
viru
addit
sequenc
clone
number
condit
scale
project
may
led
minor
variant
sequenc
escap
analysi
anoth
factor
possibl
affect
stabil
viral
genom
administr
antivir
drug
ribavirin
ribavirin
enhanc
mutagensi
rna
virus
address
therefor
artifici
effect
ribavirin
sarscov
mutant
spectrum
remain
clarifi
genet
variat
sarscov
remain
limit
relat
mani
rna
virus
hcv
mhv
probabl
reason
sarscov
caus
acut
selflimit
infect
may
prevent
persist
longterm
mutant
develop
vivo
occur
chronic
rna
viral
infect
notabl
modul
protein
remain
conserv
eg
fusionimport
hr
domain
although
variat
may
predict
chang
protein
function
featur
obviou
correl
exist
mutat
clinic
diseas
manifest
limit
data
report
instead
variat
profil
close
correl
epidemiographi
eg
patient
infect
one
hospit
conclus
report
new
variant
site
gene
sar
coronaviru
possibl
exist
sarscov
quasispeci
patient
though
limit
number
knowledg
further
understand
emerg
viru
